Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E. coli asparaginase: a retrospective analysis within the ALL-BFM trials
Authors:
O. Hrodek
Published in the journal:
Transfuze Hematol. dnes,18, 2012, No. 1, p. 47.
Category:
Selection of press reports and books
Štítky
Haematology Internal medicine Clinical oncologyČlánok vyšiel v časopise
Transfusion and Haematology Today
2012 Číslo 1
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- The Importance of Hydration in Wound Healing
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Najčítanejšie v tomto čísle
- Asymptomatic pituitary macroadenoma oppressing optic chiasm – ‘incidentaloma‘ – identified within diagnostical staging of patient with primary extranodal diffuse large B-cell lymphoma of orbit and paranasal sinuses – a case report
- The role of physical activity in patients suffering from haematological malignancies
- Mobilization of hematopoetic stem cells using plerixafor - experience of the Czech Republic transplantation centers
- Prevalence of red blood cell and HLA antibodies in multi-transfused haematological patients